-
TruColour Bandages® Continues to Set Benchmark with PFAS-Free Products, Amid Growing Industry Safety Concerns
“Inclusion since inception: Bandages that match the color of your skin, while also safe and environmentally responsible.”GRAND RAPIDS, Mich., April 16, 2024 /PRNewswire/ — Amidst alarming revelations from a recent study conducted at Carnegie Mellon, TruColour Bandages continues to distinguish itself by offering a whole range of PFAS-free wound care solutions. As litigation continues against industry
-
GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias with or without Inhibitors
Damon R. Race, President & CEO RALEIGH, N.C., April 16, 2024 /PRNewswire/ — GeneVentiv Therapeutics, developer of GENV-HEM (AAV8.FVa) for all hemophilias, announced today it has been awarded a Direct to Phase II Small Business Innovation Research (SBIR) grant for approximately $2,500,000 from the National Heart Lung Blood Institute (NHLBI) at the National Institutes of
-
Davis Phinney Foundation and Michael J. Fox Foundation: NEW Exercise Guidelines for Parkinson’s: Taking the Next Step, Putting Guidelines into Action with Urban Poling Inc.
TORONTO, April 15, 2024 /PRNewswire/ — The Davis Phinney Foundation and Michael J Fox Foundation have recently released exercise guidelines for people with Parkinson’s through informative and inspiring webinars. Studies have shown that there is a definite correlation between exercise and its beneficial impact on the management of Parkinson’s disease, and a 2024 pilot study from Yale University indicates
-
Dr. Paul Savage Unveils Pioneering Plasma Exchange Protocol: Reverses Toxins & Inflammation
For the first time in medical history, a promising procedure reveals life-changing benefits: it decreases heavy metals by up to 100%, drastically reduces inflammation, and significantly improves biomarkers of health by up to 95%. CHICAGO, April 11, 2024 /PRNewswire/ — New research indicates plasma exchange therapy reverses toxins and increases lifespan. In a landmark presentation at
-
Recommendations for Head and Neck Cancer Awareness Month from the American Board of Oral and Maxillofacial Surgery
To promote public awareness of head and neck cancer, board-certified oral and maxillofacial surgeons share facts and tips CHICAGO, April 11, 2024 /PRNewswire/ — The Executive Board and Diplomates of the American Board of Oral and Maxillofacial Surgery (ABOMS) recognize Head and Neck Cancer Awareness Month in April. Many ABOMS Diplomates are experts in head and neck
-
CViConnect Partners with The Children’s Home of Pittsburgh & Lemieux Family Center to Promote Awareness of Cortical Visual Impairment (CVI)
New Technology Development and Extended Partnership Leads to Extended Relationship LEAWOOD, Kan., April 11, 2024 /PRNewswire/ — CViConnect (cviconnect.co and pro.cviconnect.co), based in Leawood, Kansas, and provider of the industry-leading app to help teachers and parents assess and improve the eyesight of children with Cortical Visual Impairment (CVI), announced today the partnership with The Children’s Home of
-
Stamford Pharmaceuticals Inc Announces the First Patient to Be Treated with SP-002 in Combination with Erivedge® in a Phase 2 Study in Locally Advanced BCC Subjects
AUSTIN, Texas, April 11, 2024 /PRNewswire/ — Stamford Pharmaceuticals Inc, a clinical-stage biotechnology company developing science-driven immune therapies, today announced initiation of its locally advanced basal cell carcinoma (laBCC) trial (NCT06344052). The study will evaluate SP-002, an adenoviral-based immunotherapy, in combination with Roche’s vismodegib (Erivedge®), a Hedgehog Pathway inhibitor (HHPI), approved for the treatment of adult
-
Possible New Hope for Metastatic Cancer Patients: Food and Drug Administration Grants Approval for Clinical Trials For Lamassu’s Groundbreaking Cancer Treatment Protocol
CLEVELAND, April 11, 2024 /PRNewswire/ — More hope for successfully combating some of the deadliest cancers. Lamassu Biotech is proud to announce its pioneering effort to combat locally advanced metastatic p53 wild-type tumors has earned investigational new drug application (IND) approval from the Food and Drug Administration (FDA) to proceed in initiate Phase 1/2a clinical trials.
-
Certify Health’s Revolutionary Facecheck Takes HIMSS Conference by Storm
GAITHERSBURG, Md., April 10, 2024 /PRNewswire/ — Facecheck garnered huge interest at HIMSS this year, with attendees experiencing the power of the groundbreaking facial recognition system in real time. Facecheck is the latest in a range of innovations developed by Certify Health to transform patient experience, increasing efficiency and reducing administrative burden in patient authentication
-
Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Revolutionary Anti-Inflammatory Injectable
Sen-Jam Pharmaceutical has entered their third development, manufacturing, distribution and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising multi-use anti-inflammatory injectable. HUNTINGTON, N.Y., April 10, 2024 /PRNewswire/ — Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules
